Optimising Asparaginase Use and Managing Hypersensitivity in Australasia—A Clinical Practice Guideline From the Australian and New Zealand Children's Haematology/Oncology Group
Asparaginase is a critical component of modern multi-agent chemotherapy regimens for paediatric acute lymphoblastic leukaemia and lymphoblastic lymphoma, with inadequate exposure leading to inferior patient outcomes.
Keywords:
Child disability; asparaginase; hypersensitivity, cancer
Abstract:
Asparaginase is a critical component of modern multi-agent chemotherapy regimens for paediatric acute lymphoblastic leukaemia and lymphoblastic lymphoma, with inadequate exposure leading to inferior patient outcomes.